TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients
Authors:
Open Access
- 23 September 2020
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 39 (1) , 1-15
Abstract
Background: SARS-coronavirus-2 enters host cells through binding of the Spike protein to ACE2 receptor and subsequent S priming by the TMPRSS2 protease. We aim to assess differences in both ACE2 and TMPRSS2 expression in normal tissues from oral cavity, pharynx, larynx and lung tissues as well as neoplastic tissues from the same areas. Methods: The study has been conducted using the TCGA and the Regina Elena Institute databases and validated by experimental model in HNSCC cells. We also included data from one COVID19 patient who went under surgery for HNSCC. Results: TMPRSS2 expression in HNSCC was significantly reduced compared to the normal tissues. It was more evident in women than in men, in TP53 mutated versus wild TP53 tumors, in HPV negative patients compared to HPV positive counterparts. Functionally, we modeled the multivariate effect of TP53, HPV, and other inherent variables on TMPRSS2. All variables had a statistically significant independent effect on TMPRSS2. In particular, in tumor tissues, HPV negative, TP53 mutated status and elevated TP53-dependent Myc-target genes were associated with low TMPRSS2 expression. The further analysis of both TCGA and our institutional HNSCC datasets identified a signature anti-correlated to TMPRSS2. As proof-of-principle we also validated the anti-correlation between microRNAs and TMPRSS2 expression in a SARS-CoV-2 positive HNSCC patient tissues Finally, we did not find TMPRSS2 promoter methylation. Conclusions: Collectively, these findings suggest that tumoral tissues, herein exemplified by HNSCC and lung cancers might be more resistant to SARS-CoV-2 infection due to reduced expression of TMPRSS2. These observations may help to better assess the frailty of SARS-CoV-2 positive cancer patients.Keywords
All Related Versions
Funding Information
- AIRC (IG 2017 - ID. 20613)
- Alliance against Cancer
- Regione Lazio
- MAECI Italy/USA bilateral grant program
This publication has 38 references indexed in Scilit:
- YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteinsEMBO Reports, 2015
- Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancerEpigenetics & Chromatin, 2015
- MYC Activation Is a Hallmark of Cancer Initiation and MaintenanceCold Spring Harbor Perspectives in Medicine, 2014
- Metabolic control of YAP and TAZ by the mevalonate pathwayNature Cell Biology, 2014
- Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patientsAnnals of Oncology, 2013
- MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of functionCell Death & Differentiation, 2011
- The molecular biology of head and neck cancerNature Reviews Cancer, 2010
- Type II Transmembrane Serine ProteasesJournal of Biological Chemistry, 2009
- Head and neck cancerThe Lancet, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002